Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Nov 08, 2023 4:34pm
109 Views
Post# 35724571

RE:RE:RE:RE:History Repeats

RE:RE:RE:RE:History RepeatsONCInvestor - The first three patients on Bracelet-1 would have been those taking the triplet therapy - run-in trial done for safety reasons... The first OS data they had should have been from these three patients and ONCY would have known damn well how this compared with Pela+Pax alone.

They kept telling investors that this trial was done to derisk the prospective Phase III, and to ensure a competitive landscape, to ensure they could get the best deal for a partnership.

So it failed to engage a CPI partner... 5 years wasted. Now they claim to be running a Phase III with just Pela + Pax, so why not start now, they have a SPA in place, and two randomised trials showing it works, yet STILL, we have no one willing to pay for this trial... it stinks.

Then there's the whole issue with Adlai Nortye, that brilliant company who have run their bridging trial for Chinese patients, found an efficacy signal, and have gone radio silent on their own Phase III... What a f&*()* mess.

Now they're trying to drum up another competitive scenario, with yet another Phase II with another combo. All this means is more delay. WHERE is this fabled Phase III...?

And for those who say, oh, but pps is not important... well it is when you want to raise cash, or you're about to be delisted for the second time... Yeah, getting backl on the Nasdaq was a strike of genius, what are we down since then 70% - and how much further along is an mBC phase iII...

I completely agree. this bunch of clowns seems incapable of getting the job done. 1 molecule in 26 years... 

Crispr technology was only discovered 10 years ago... and yet the first approvals are imminent... Go back to your beach in Thailand Matt, mummy is fine.


<< Previous
Bullboard Posts
Next >>